What's Happening?
RedChip Companies will feature interviews with NioCorp Developments Ltd. and Atossa Therapeutics, Inc. on the RedChip Small Stocks, Big Money show airing on Bloomberg TV. NioCorp's CEO, Mark Smith, will discuss the Elk Creek Project in Nebraska, a critical minerals mine expected to produce niobium, scandium, titanium, and potentially rare earth oxides. The project is supported by a U.S. Department of Defense grant and an $800 million U.S. Export-Import Bank debt financing application. Atossa Therapeutics' CEO, Dr. Steven Quay, will present their lead clinical candidate, (Z)-endoxifen, aimed at redefining breast cancer treatment. The interviews will highlight the companies' strategic approaches and potential long-term shareholder value.
Why It's Important?
The airing of these interviews on Bloomberg TV provides significant exposure for NioCorp and Atossa Therapeutics, potentially attracting investor interest and support. NioCorp's Elk Creek Project is crucial for establishing a domestic supply chain for critical minerals, which are essential for clean energy, aerospace, and defense applications. Atossa's focus on breast cancer treatment innovation addresses a critical need in healthcare, potentially improving patient outcomes and offering new therapeutic options. Both companies are positioned to contribute to their respective industries' growth and development, impacting economic and technological advancements.
What's Next?
NioCorp is advancing towards the construction phase of the Elk Creek Project, with strong backing from state, federal, and local entities. Atossa Therapeutics is progressing with multiple Phase 2 studies for (Z)-endoxifen, aiming to achieve clinical milestones that could lead to regulatory approvals and market entry. Investors and stakeholders will be closely monitoring these developments, as successful execution could lead to increased market presence and financial returns.
